Hypertension is often called the silent killer because hypertensive sufferers in general do not experience complaints and only feels complaints after being complicated. The prevalence of hypertension in Indonesia is based on the results of the 2018 Basic Health Research, which amounted to 34.1%. Hypertension has many variants of therapy, besides hypertension therapy takes a lifetime. The high prevalence of hypertension in Indonesia causes the burden of costs borne by the government to make blood pressure controlled. The cost of the costs will be greater if complications occur so that the effectiveness and cost analysis needs to be done so that the cost-effective therapy can be obtained. The purpose of this study was to determine the results of the Cost Effectiveness Analysis (CEA) study using Captopril and Amlodipine based on the perspective of health care providers (Puskesmas) in primary hypertensive patients outpatient at Gondokusuman I. This study was conducted using a cohort observational non-experimental study design with retrospective data collection. Data sources are secondary data from medical records. The effectiveness of the anti-hypertensive treatment Amlodipine and Captopril is a decrease in blood pressure until it reaches the target of therapy. This research was conducted based on the perspective of the health care provider (Puskesmas). The calculated cost component is direct medical costs. The research subjects were 121 patients who met the inclusion criteria. The results showed that treatment of primary hypertension using Captopril 12.5 mg was absolutely more cost-effective than Amlodipine 10 mg. Likewise with Captopril 25 mg compared to Amlodipin 5 mg and Captopril 25 mg compared with Amlodipine 10 mg. Whereas for Amlodipine 5 mg and Captopril 12.5 mg ICER test is needed. ICER value is IDR 2,500